Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Corporate Update on March 1, 2021

Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will release its financial results for the quarter and year ended December 31, 2020, after market close on March 1, 2021. Following this announcement, a conference call and webcast will take place at 4:30 p.m. ET. Arcturus is focused on developing mRNA medicines and vaccines for infectious diseases, with products targeting COVID-19, Influenza, and rare liver and respiratory diseases. The company utilizes its proprietary LUNAR® and STARR™ technologies and is supported by a strong patent portfolio and various collaborations.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will provide a corporate overview and release its financial results for the quarter and year ended December 31, 2020 after the market close on March 1 and will also host a conference call and webcast at 4:30 pm Eastern Time on Monday, March 1, 2021.

Monday, March 1 @ 4:30 p.m. ET
Domestic:			877-407-0784
International:			201-689-8560
Conference ID:			13716298
Webcast:			http://public.viavid.com/index.php?id=143486

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, and Cystic Fibrosis along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (209 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210219005138/en/

FAQ

When will Arcturus Therapeutics announce its financial results?

Arcturus Therapeutics will announce its financial results for the quarter and year ended December 31, 2020, after market close on March 1, 2021.

What is the conference call date and time for Arcturus Therapeutics?

The conference call for Arcturus Therapeutics will be held on March 1, 2021, at 4:30 p.m. ET.

What technologies does Arcturus Therapeutics utilize?

Arcturus Therapeutics utilizes proprietary technologies such as LUNAR® lipid-mediated delivery and STARR™ mRNA Technology.

What types of diseases does Arcturus Therapeutics focus on?

Arcturus Therapeutics focuses on infectious disease vaccines, as well as liver and respiratory rare diseases.